Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of AK104 plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for PD-L1-negative NSCLC
CTR20232128Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Jan 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Jan 2024; status: active.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20232128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232128.